Envoy Medical Reaches Three-Month Milestone for All 56 Patients in Acclaim Cochlear Implant Clinical Trial

Completion of Three-Month Milestone Highlights Clinical Trial Advancement

Envoy Medical confirmed that all 56 patients enrolled in the pivotal clinical trial assessing the investigational Acclaim fully implanted cochlear implant have completed their three-month follow-up visits. The company stated this milestone is a significant step in the clinical development process and demonstrates its ability to effectively execute the study protocol.

The company continues to collect safety and other key study data as part of the ongoing pivotal trial. This data will be incorporated into Envoy Medical’s planned PMA submission to the FDA, a critical regulatory step for the device’s potential commercialization in the U.S.

CEO Highlights Progress Toward FDA Submission

Brent Lucas, Chief Executive Officer of Envoy Medical, described the three-month milestone as proof of the company’s operational execution. He stated, "Each milestone achieved brings us one big step closer to our next major goal – submission of our PMA application to the FDA," underscoring Envoy Medical’s commitment to advancing fully implanted cochlear implants in the U.S. market.

Mr. Lucas’s remarks emphasize that this clinical milestone validates the company’s trial management and regulatory approach, positioning the three-month completion as an important data collection checkpoint rather than a final endpoint.

Projected Timeline for Upcoming Clinical Trial Milestones

Envoy Medical outlined anticipated timelines for the remaining pivotal trial phases, expecting to reach the six-month visit milestone by late 2026 and complete the 12-month visit milestone by April 2027. These milestones are essential for ongoing data collection and safety evaluations.

The sequential milestones reflect the trial’s structured design and suggest Envoy Medical has established achievable timelines based on current patient enrollment and follow-up rates. This schedule offers transparency to investors regarding clinical development progress and the timing of key data for the planned PMA submission.

Acclaim Cochlear Implant Technology and Intended Use

The Acclaim fully implanted cochlear implant is intended to treat adults with severe to profound sensorineural hearing loss inadequately managed by conventional hearing aids. The device utilizes a sensor that leverages the ear’s natural anatomy to capture sound, rather than a traditional microphone, distinguishing it from standard hearing devices.

Envoy Medical describes the Acclaim CI as a pioneering fully implanted hearing device. It received FDA Breakthrough Device Designation in 2019, a status that may expedite the review process. The company notes the device remains investigational and is limited by federal law to investigational use.

Envoy Medical’s Established Hearing Device Portfolio

Envoy Medical operates within the hearing health sector and markets the Esteem fully implanted active middle ear implant (FI-AMEI), which received FDA approval and has been commercially available in the U.S. since 2010. The Esteem device targets adults with moderate to severe sensorineural hearing loss, providing continuous hearing without external components or in-ear placement.

The company’s commercial experience with Esteem offers operational and clinical expertise that supports the development and potential commercialization of the Acclaim cochlear implant. This positions Envoy Medical as an established medical device company with a history of delivering fully implanted hearing solutions.

FDA Regulatory Strategy and PMA Submission Plans

Envoy Medical’s strategy involves gathering comprehensive safety and efficacy data through the pivotal trial, followed by submission of a PMA application to the FDA. The PMA pathway is required for novel medical devices seeking FDA approval prior to U.S. commercialization. The company plans to include complete trial data in its submission.

Forward-looking statements mention modular PMA submissions, indicating Envoy Medical may pursue a phased FDA review approach. This could enable earlier feedback on specific device components or data segments, although no detailed plans on modular filing timing or structure were disclosed.

Breakthrough Device Designation and Regulatory Context

The Acclaim cochlear implant’s FDA Breakthrough Device Designation, granted in 2019, recognizes its potential to offer more effective treatment for severe or debilitating conditions compared to existing options. This designation facilitates priority review and enhanced FDA-manufacturer interactions during development.

Envoy Medical emphasizes this regulatory status as integral to its strategy and timeline expectations. While the Breakthrough designation does not guarantee approval, it highlights the device’s potential clinical importance.

Clinical Trial Enrollment and Patient Cohort

The pivotal trial enrolled 56 patients, all of whom have completed the three-month follow-up milestone. The announcement does not provide further details on patient demographics, inclusion/exclusion criteria, or trial site locations. Operational specifics such as the number of trial sites were not disclosed.

The completion of three-month visits by all patients indicates strong retention at this stage. No information was provided on patient discontinuations, adverse events, or complications encountered during the trial.

Hearing Health Market Landscape and Competitive Positioning

Envoy Medical competes in the hearing health and audiology sector, which includes conventional hearing aids, bone conduction devices, cochlear implants, and other hearing restoration technologies. The Acclaim fully implanted cochlear implant is positioned as an innovative solution within the cochlear implant category, targeting patients seeking fully implanted devices without external components.

The company’s focus on fully implanted hearing solutions highlights advantages in discretion, convenience, and continuous use compared to traditional hearing aids or cochlear implants with external parts. The announcement does not provide comparative performance, safety, or user outcome data versus existing hearing technologies.